Program
vicadrostat
Also written as “BI 690517”, “Vicadrostat” and “Vicadrostat + empagliflozin”.
In Boehringer Ingelheim’s pipeline, Aldosterone synthase inhibitor / SGLT2 inhibitor
. Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus, Type 2 · Diabetic Nephropathies · Liver Diseases, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 165 open or running | phase 3since May 10, 2024 | Sep 1, 2016 | Dec 11, 2026phase 1 · NCT07845630 |
- Named in Boehringer Ingelheim’s own pipeline as
Vicadrostat (BI 690517)
, phase 3, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 1, 2016.
- Jun 30, 2017Phase 1 study in HealthyNCT03206632 · 56 enrolled · Korea, Republic of
- Jul 20, 2018Phase 1 study in HealthyNCT03608072 · 36 enrolled · Japan
- Jan 5, 2022Phase 2 study in Renal Insufficiency, ChronicNCT05182840 · 714 enrolled · United States, Argentina, Australia and more
- Aug 24, 2022Phase 1 study in HealthyNCT05515588 · 14 enrolled · Netherlands
- Feb 8, 2023Phase 1 study in Liver DiseasesNCT05731908 · 28 enrolled · United States
- Feb 29, 2024Named vicadrostatINNProposed as its International Nonproprietary Name in WHO's List 130 · before, BI 690517
- May 10, 2024Phase 3 study in Heart FailureNCT06424288 · 6,712 planned · United States, Argentina, Australia and more
- Jul 29, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06531824 · 8,371 enrolled · United States, Argentina, Australia and more
- Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicNCT06926660 · 492 enrolled · United States, Argentina, Australia and more
- Apr 17, 2025Phase 3 study in Heart FailureNCT06935370 · 4,200 planned · United States, Argentina, Belgium and more
- Jun 17, 2025Phase 1 study in HealthyNCT07035457 · 15 enrolled · Germany
- Jul 11, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07064473 · 11,800 planned · United States, Argentina, Australia and more
- Aug 19, 2025Phase 1 study in HealthyNCT07133399 · 32 enrolled · Germany
- Apr 1, 2026Phase 1 study in HealthyNCT07513207 · 45 enrolled · Germany
- Sep 23, 2026Phase 1 study in HealthyNCT07845630 · 36 planned · Germany
Ahead
- Dec 11, 2026Primary completion: phase 1 study in HealthyNCT07845630
- Dec 31, 2026Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT06531824
- May 22, 2028Primary completion: phase 3 study in Heart FailureNCT06424288
- Feb 4, 2029Primary completion: phase 3 study in Heart FailureNCT06935370
TargetBeta
“Aldosterone synthase inhibitor / SGLT2 inhibitor”the company's pipeline, read by Claude · source
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07845630Healthy · Germany | 1 | Recruiting | Dec 11, 2026 | 36 |
| NCT07513207Healthy · Germany | 1 | Completed | Jul 24, 2026 | 45 |
| NCT07133399Healthy · Germany | 1 | Completed | Oct 22, 2025 | 32 |
| NCT07064473Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Recruiting | Dec 14, 2029 | 11,800 |
| NCT07035457Healthy · Germany | 1 | Completed | Aug 7, 2025 | 15 |
| NCT06935370Heart Failure · United States, Argentina, Belgium and more | 3 | Recruiting | Feb 4, 2029 | 4,200 |
| NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Aug 14, 2026 | 492 |
| NCT06531824Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 31, 2026 | 8,371 |
| NCT06424288Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | May 22, 2028 | 6,712 |
| NCT05731908Liver Diseases · United States | 1 | Completed | Apr 13, 2023 | 28 |
| NCT05515588Healthy · Netherlands | 1 | Completed | Nov 17, 2022 | 14 |
| NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Jun 19, 2023 | 714 |
| NCT03608072Healthy · Japan | 1 | Completed | Jan 31, 2019 | 36 |
| NCT03206632Healthy · Korea, Republic of | 1 | Completed | Oct 13, 2017 | 56 |
| NCT03165240Diabetic Nephropathies · Denmark, France, Germany and more | 1 | Completed | Apr 16, 2020 | 62 |
| NCT02891148Healthy · Germany | 1 | Completed | Dec 12, 2016 | 50 |
How it is read
Names in the registry
- “BI 690517”, 8 entries
- “Vicadrostat”, 5 entries
- “vicadrostat”, 2 entries
- “Vicadrostat + empagliflozin”, 1 entry
- “vicadrostat / empagliflozin combination 1”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 3 studies
- Heart Failure, 2 studies
- Diabetes Mellitus, Type 2, 1 study
- Diabetic Nephropathies, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.